<< Back
April 6, 2017 at 8:00 AM EDT

Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer

BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 6, 2017-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of George Migausky as interim Chief Financial Officer. Mr. Migausky brings more than 30 years of experience in senior financial management to Ocular Therapeutix. In his new role, he will have Ocular’s financial and administrative groups reporting to him while the Company continues to evaluate candidates for the permanent CFO role. Mr. Migausky replaces Brad Smith who recently relinquished his role as CFO at the Company.

“George is a highly regarded financial professional, offering extensive expertise at high-growth private and public life sciences and technology,” said Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman of Ocular. “We believe his insights will be invaluable as we continue to undertake pre-commercialization activities for DEXTENZA™ in advance of the July 19th PDUFA date and as we make further substantial progress across our additional drug product development programs.”

Dr. Sawhney added, “On behalf of everyone at Ocular Therapeutix, I would also like to thank Brad for his contributions at Ocular. He has been an essential part of Ocular’s success and growth over the past three years, and we wish him the best of luck in his future endeavors.”

Most recently, Mr. Migausky was Executive Vice President and Chief Financial Officer of Dyax Corp., through its $6+ billion merger with Shire plc in 2016. Previously, Mr. Migausky served as the CFO of Wellstat Management Company, a firm responsible for strategy and operations of an affiliated group of five life science companies. Prior to this, he held CFO positions at several public and private companies, including IGEN International, Inc., where he played a pivotal role in the company’s IPO and subsequent $1.5 billion merger with F. Hoffman LaRoche. Mr. Migausky is on the Boards of Dimension Therapeutics, Inc. and Hyperion Catalysis International, and is a trustee at the Massachusetts Ear and Eye Infirmary. He received his M.B.A. degree from Babson College and B.S. degree from Boston College.

“I am thrilled that Amar and his team have asked me to step into this key role at Ocular,” said Mr. Migausky. “I look forward to working closely with management and contributing to the Company’s advancement as it plans for a potential product launch and commercialization.”

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation occurring after ophthalmic surgery. The FDA has accepted the Company’s NDA resubmission for DEXTENZA for the treatment of ocular pain occurring after ophthalmic surgery and has established a target PDUFA date of July 19, 2017. Ocular Therapeutix is also pursuing additional indications for DEXTENZA. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company including the development and regulatory status of the Company’s product candidates, such as the Company’s expectations and plans regarding regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA™ for post-surgical ocular inflammation and pain, including our expectations regarding the NDA filed with the FDA, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the potential utility of any of the Company’s product candidates, potential commercialization of the Company’s product candidates, the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Source: Ocular Therapeutix, Inc.

Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
Medical Dynamics
Sandra Correa, 646-599-8637
Media and Business Group Director
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Marketing and Commercial Operations